180 related articles for article (PubMed ID: 33107373)
1. Evaluation of the efficacy and safety of arsenic trioxide dosing in obese patients with acute promyelocytic leukemia.
Barsoum B; Henneman A; Ahmad S; Ghiuzeli C
Leuk Lymphoma; 2021 Mar; 62(3):703-708. PubMed ID: 33107373
[TBL] [Abstract][Full Text] [Related]
2. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
Jen WY; Sasaki K; Rausch CR; DiNardo CD; Kadia TM; Yilmaz M; Borthakur G; Alvarado Y; McCue D; McCue D; Kantarjian HM; Ravandi F
Leuk Lymphoma; 2024 Mar; 65(3):378-382. PubMed ID: 38054837
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
Zacholski K; Hambley B; Hickey E; Kashanian S; Li A; Baer MR; Duong VH; Newman MJ; DeZern A; Gojo I; Smith BD; Levis MJ; Varadhan R; Gehrie E; Emadi A; Ghiaur G
J Oncol Pharm Pract; 2022 Sep; 28(6):1340-1349. PubMed ID: 34134554
[TBL] [Abstract][Full Text] [Related]
4. Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
Freyer CW; Peterson CE; Man Y; Przespolewski A; Baron J; Luger SM
Leuk Lymphoma; 2021 Mar; 62(3):696-702. PubMed ID: 33106056
[TBL] [Abstract][Full Text] [Related]
5. Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment.
Zhang Z; Zhang S; Zhang F; Zhang Q; Wei H; Xiu R; Zhao Y; Sui M
Biol Trace Elem Res; 2024 Jan; 202(1):122-132. PubMed ID: 37097388
[TBL] [Abstract][Full Text] [Related]
6. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
9. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
[No Abstract] [Full Text] [Related]
10. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
11. Current management of newly diagnosed acute promyelocytic leukemia.
Cicconi L; Lo-Coco F
Ann Oncol; 2016 Aug; 27(8):1474-81. PubMed ID: 27084953
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial myopathy caused by arsenic trioxide therapy.
Echaniz-Laguna A; Benoilid A; Vinzio S; Fornecker LM; Lannes B; Goullé JP; Broly F; Mousson de Camaret B
Blood; 2012 May; 119(18):4272-4. PubMed ID: 22427206
[TBL] [Abstract][Full Text] [Related]
13. Acute promyelocytic leukemia: where did we start, where are we now, and the future.
Coombs CC; Tavakkoli M; Tallman MS
Blood Cancer J; 2015 Apr; 5(4):e304. PubMed ID: 25885425
[TBL] [Abstract][Full Text] [Related]
14. The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.
Zhu HH; Guo ZP; Jia JS; Jiang Q; Jiang H; Huang XJ
Leuk Res; 2018 Feb; 65():14-19. PubMed ID: 29232592
[TBL] [Abstract][Full Text] [Related]
15. Sulfhydryl compound levels are associated with ATO-induced side effects in acute promyelocytic leukemia patients.
Sui M; Wei H; Shen X; Gao K; Zhang Z; Zhang Q
Hematology; 2023 Dec; 28(1):2231738. PubMed ID: 37417768
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
17. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
18. Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid.
Singh C; Saini M; Jain A; Lad D; Prakash G; Khadwal A; Naseem S; Malhotra P
Blood Cancer J; 2024 Jan; 14(1):14. PubMed ID: 38238308
[No Abstract] [Full Text] [Related]
19. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
[TBL] [Abstract][Full Text] [Related]
20. Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
Kulkarni UP; Selvarajan S; Fouzia NA; Lionel S; Nair SC; Balasubramanian P; Mani T; Abraham A; George B; Mathews V
Blood Cancer J; 2023 Jun; 13(1):94. PubMed ID: 37349334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
